The peptide hormone glucagon, discovered in late 1922, is secreted from pancreatic alpha
cells and is an essential regulator of metabolic homeostasis. This review summarises …

The introduction of the highly potent incretin receptor agonists semaglutide and tirzepatide
has marked a new era in the treatment of type 2 diabetes and obesity. With normalisation of …

Many peptide hormones form an α-helix on binding their receptors,,–, and sensitive methods
for their detection could contribute to better clinical management of disease. De novo protein …

Hundred years after the discovery of glucagon, its biology remains enigmatic. Accurate
measurement of glucagon has been essential for uncovering its pathological hypersecretion …

Both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD) strongly associate
with increasing body mass index, and together these metabolic diseases affect millions of …

Glucagon and insulin are the main regulators of blood glucose. While the actions of insulin
are extensively mapped, less is known about glucagon. Besides glucagon's role in glucose …

Type 2 diabetes is a disease involving both inadequate insulin levels and increased
glucagon levels. While glucagon and insulin work together to achieve optimal plasma …

The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style
and inflammation, which have a major impact on the severity of the clinicopathologic …

Mahvash disease is an exceedingly rare genetic disorder of glucagon signaling
characterized by hyperglucagonemia, hyperaminoacidemia, and pancreatic α-cell …

Discovered almost simultaneously with insulin, glucagon is a pleiotropic hormone with
metabolic action that goes far beyond its classical role to increase blood glucose. Albeit best …